度维利塞联合罗米地辛治疗复发或难治性外周及皮肤T细胞淋巴瘤的真实世界证据
这项多中心真实世界研究纳入38例复发或难治性外周T细胞淋巴瘤患者,接受度维利塞联合罗米地辛治疗,中位3周期后总缓解率61%、完全缓解率47%,nTFH亚型缓解率更高,11例成功桥接至异基因造血干细胞移植,耐受性良好。
要点
- 38例R/R PTCL患者接受度维利塞联合罗米地辛,中位3周期后ORR 61%、CRR 47%。
- nTFH亚型ORR 82% vs 非nTFH 43%,CRR 71% vs 29%。
- 11例患者经duv/romi桥接至异基因造血干细胞移植。
核心结论
- 这些发现强化了度维利塞联合罗米地辛在高危复发或难治性外周T细胞淋巴瘤中的疗效及其桥接至治愈性造血干细胞移植的作用。
研究设计与样本
- 多中心真实世界研究,纳入38例复发或难治性外周T细胞淋巴瘤患者。
主要发现
- 诊断时中位年龄62岁;组织学亚型包括nTFH 17例、PTCL-NOS 14例、皮肤TCL 3例、结外NK/TCL 1例、ALK阴性ALCL 1例、成人T细胞白血病/淋巴瘤1例、肝脾TCL 1例。
- 既往治疗中位数为1(IQR 1-2);15例复发、23例难治,其中8例既往接受过HSCT(5例自体、3例异基因)。
- 中位3周期(IQR 2-4)后ORR 61%、CRR 47%;nTFH vs 非nTFH的ORR为82% vs 43%,CRR为71% vs 29%。
- nTFH vs 非nTFH的中位PFS为11 vs 3.3个月,中位OS(HSCT删失)为16 vs 8.3个月。
- 中位至缓解时间1.9个月(IQR 1.7-2.6),缓解持续时间21个月,至下一治疗时间17个月;11例桥接至异基因HSCT。
临床怎么用
- 作者认为这些发现强化了度维利塞联合罗米地辛在高危复发或难治性外周T细胞淋巴瘤中的疗效及其桥接至治愈性造血干细胞移植的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) require lineage-specific therapies to bridge to hematopoietic stem cell transplantation (HSCT). A previous phase 1/2 study of duvelisib/romidepsin (duv/romi) reported an overall response rate (ORR) of 58% and a complete response rate (CRR) of 42% with reduced grade 3 to 4 transaminitis (14%). We report real-world duv/romi outcomes in a multicenter, 38-patient R/R PTCL cohort. The median age at diagnosis was 62 years. Histological subtypes included nodal T follicular helper cell (nTFH; n = 17), PTCL-not otherwise specified (n = 14), cutaneous T-cell lymphoma (TCL; n = 3), extranodal natural killer/TCL (n = 1), ALK-negative anaplastic large cell lymphoma (n = 1), adult T-cell leukemia/lymphoma (n = 1), and hepatosplenic TCL (n = 1). The median previous therapy count was 1 (interquartile range [IQR], 1-2); 15 patients relapsed and 23 were refractory to prior treatment, including 8 prior HSCT (5 autologous, 3 allogeneic). After a median of 3 cycles (IQR, 2-4), ORR and CRR were 61% and 47%, respectively, with higher ORR (82% vs 43%) and CRR (71% vs 29%) in nTFH versus non-nTFH. The median progression-free survival and overall survival (HSCT-censored) were 11 and 16 months for nTFH, versus 3.3 and 8.3 months for non-nTFH. The median time to response was 1.9 months (IQR, 1.7-2.6), duration of response was 21 months, and time to next therapy was 17 months. After duv/romi, 11 patients bridged to allo-HSCT. Treatment was well tolerated; the most common grade 3 to 4 toxicities were lymphopenia (n = 15), neutropenia (n = 15), thrombocytopenia (n = 10), and transaminitis (n = 6), seldom leading to discontinuation (n = 4) or death (n = 1). These findings reinforce duv/romi's efficacy and bridging role to curative HSCT in high-risk R/R PTCL.
引用
- Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025. PMID: 40526834. doi:10.1182/bloodadvances.2025016347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。